Younos Ibrahim H, Abe Fuminori, Talmadge James E
a Department of Clinical Pharmacology , Menoufia University , Al-Minufya , Egypt.
b Department of Pharmacology and Clinical Pharmacy , College of Medicine and Health Sciences, Sultan Qaboos University , Muscat , Oman.
Leuk Lymphoma. 2015;56(8):2251-63. doi: 10.3109/10428194.2014.987141. Epub 2015 Jan 21.
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells at various stages of differentiation/maturation that have a role in cancer induction and progression. They function as vasculogenic and immunosuppressive cells, utilizing multiple mechanisms to block both innate and adaptive anti-tumor immunity. Recently, their mechanism of action and clinical importance have been defined, and the cross-talk between myeloid cells and cancer cells has been shown to contribute to tumor induction, progression, metastasis and tolerance. In this review, we focus on the role of MDSCs in hematologic malignancies and the therapeutic approaches targeting MDSCs that are currently in clinical studies.
髓源性抑制细胞（MDSCs）是处于不同分化/成熟阶段的未成熟髓样细胞的异质群体，在癌症的诱导和进展中发挥作用。它们作为血管生成和免疫抑制细胞，利用多种机制阻断先天性和适应性抗肿瘤免疫。最近，它们的作用机制和临床重要性已得到明确，并且已表明髓样细胞与癌细胞之间的相互作用有助于肿瘤的诱导、进展、转移和耐受。在本综述中，我们重点关注MDSCs在血液系统恶性肿瘤中的作用以及目前正在临床研究中的靶向MDSCs的治疗方法。
